AstraZeneca reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share rose 18% at constant exchange rates to $2.63, ahead of the $2.48 consensus, while total revenue reached $15.38 billion, up 5% at constant exchange rates. Oncology revenue grew 16% to $7.33 billion, driven by Tagrisso, Imfinzi, and Enhertu, and Rare Disease contributed $4.9 billion, offsetting a 15% decline in the Cardiovascular, Renal & Metabolism segment due to Farxiga's loss of exclusivity in the U.S. and China pricing pressures. Management expressed confidence in reaching its $80 billion total revenue target by 2030 despite near-term headwinds. Separately, a Phase 3 study of Ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopathy failed to meet its primary endpoint, which H.C. Wainwright called a positive for competitor Omeros.
AstraZeneca PLCBeat Q2 estimates, reaffirmed 2026 outlook and $80B 2030 target.
Omeros CorporationFailed Ultomiris trial is positive for Omeros competitor.
